## KEY TAKEAWAYS
- Nourish raised $100M in Series C funding led by Menlo Ventures at a $1.75B valuation, bringing total funding to $215M since inception to scale its AI-native metabolic health platform across the U.S.
- The Series C round includes co-investors Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, and Y Combinator, signaling strong institutional backing for the virtual nutrition care model.
- Nourish operates in all 50 states with insurance partnerships covering over 200 million Americans, positioning the company to address metabolic disease affecting nearly 200 million U.S. residents linked to chronic illness and preventable mortality.
- Capital deployment will accelerate expansion of AI-powered dietitian-led clinics, with the technology platform automating care coordination while registered dietitians deliver personalized nutrition guidance, GLP-1 prescribing, and behavioral support.
- Clinical outcomes demonstrate 8% average weight loss and measurable improvements in A1C, LDL cholesterol, and blood pressure, validating the model's effectiveness in treating nutrition-related chronic disease at scale.
## DETAILED SUMMARY
Nourish, a New York-based virtual metabolic health platform, secured $100 million in Series C funding led by Menlo Ventures, valuing the company at $1.75 billion. The round accelerates the company's expansion of AI-driven nutrition care clinics throughout the United States and brings its cumulative funding to $215 million. Co-investors in the round include Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, and Y Combinator, reflecting confidence from both venture and growth equity investors in the metabolic health care market.
Nourish operates a hybrid model combining registered dietitians with artificial intelligence systems to deliver continuous preventive care for chronic metabolic diseases. The company currently serves all 50 states through telehealth delivery and has established partnerships with insurance providers that extend reach to over 200 million covered lives. This distribution advantage positions Nourish at scale within a market where nearly 200 million Americans live with metabolic-linked chronic conditions, which drive substantial healthcare spending and contribute to more than one million preventable deaths annually in the U.S.
The capital will fund expansion of the AI care platform, technology infrastructure development, and growth of the dietitian network to support increased patient volume. CEO Aidan Dewar emphasized that the U.S. healthcare system remains poorly structured to treat chronic disease at scale, with fragmented and reactive care models. Nourish's approach replaces this paradigm with coordinated, continuous metabolic care delivered through personalized nutrition guidance, clinical lab testing, medical support, and GLP-1 prescribing where clinically appropriate.
Clinical performance metrics validate the operational model's efficacy. Patients enrolled in Nourish programs achieve an average 8 percent weight loss alongside measurable improvements in A1C, LDL cholesterol, and blood pressure—key markers in metabolic and cardiovascular health. These outcomes position Nourish competitively within the growing metabolic health and chronic disease management sector, which has attracted significant venture and growth capital investment in recent years.
